Press Releases | Vertex Pharmaceuticals Newsroom

Date	Title	Additional Format
Jan 12, 2006	Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.	Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research
Jan 09, 2006	Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference —Product Candidates with Transformational Potential Highlighted—	Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
Jan 09, 2006	Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference -Product Candidates with Transformational Potential Highlighted-	Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
Jan 09, 2006	VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon --Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-950 and peg-IFN in 14-day clinical study--	VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon
Dec 16, 2005	GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir - Positive Data Presented at 45th Annual ICAAC -	GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir
Dec 13, 2005	GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain - VX-409 is first in a new class of subtype selective ion channel modulators -	GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
Dec 13, 2005	GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain - VX-409 is first in a new class of subtype selective ion channel modulators -	GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain
Dec 08, 2005	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
Dec 08, 2005	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to	FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
Dec 07, 2005	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
Dec 07, 2005	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -	Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study
Dec 05, 2005	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - Investigational New Drug Application Activated in the U.S. -	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
Dec 05, 2005	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - Investigational New Drug Application Activated in the U.S. -	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
Nov 18, 2005	FDA Approves Updated Labeling for LEXIVA - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -	FDA Approves Updated Labeling for LEXIVA
Nov 18, 2005	FDA Approves Updated Labeling for LEXIVA - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -	FDA Approves Updated Labeling for LEXIVA
Nov 11, 2005	AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S.	AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor
Nov 09, 2005	Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST.	Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting
Oct 31, 2005	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations
Oct 26, 2005	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results - VX-950 Phase Ib Combination Study Initiated - - Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved -	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results
Oct 04, 2005	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis